small win: cagrilintide stopped being a problem at week 75
small win: cagrilintide stopped being a problem at week 75. Numbers below. Ask me the boring questions, they are the useful ones.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
Which receptor family are you attributing that effect to?
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
satiety signalling rather than incretin signalling
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
read the combination arms separately from the monotherapy arms
- 1Independent purity data on this compound is sparse compared with the older…6 comments in this branch · started by u/noor_hovland